BETH ISRAEL DEACONESS MEDICAL CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1896-01-01

Employees: -

Market Cap: -

Website: https://www.bidmc.org/

Clinical Trials

A Randomized Trial to Reduce the Disparity in Live Donor Kidney Transplantation

Not Applicable

Completed

Conditions: Chronic Kidney Disease
End-stage Renal Disease

Interventions: Behavioral: Group-Based (GB) Intervention
Behavioral: Home-Based (HB) Intervention

First Posted Date: 2008-11-05

Last Posted Date: 2020-07-10

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 164

Registration Number: NCT00785265

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma

Phase 2

Completed

Conditions: Renal Cell Carcinoma
Kidney Cancer

Interventions: Drug: bevacizumab
Drug: temsirolimus

First Posted Date: 2008-10-31

Last Posted Date: 2018-01-24

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 41

Registration Number: NCT00782275

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Vanderbilt Univeristy Medical Center, Nashville, Tennessee, United States

N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients

Phase 2

Completed

Conditions: Radiocontrast Nephropathy

Interventions: Drug: N-Acetylcysteine (NAC)
Drug: 0.9% Sodium-chloride

First Posted Date: 2008-10-28

Last Posted Date: 2024-10-29

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 399

Registration Number: NCT00780962

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)

Not Applicable

Completed

Conditions: Renal Cell Carcinoma

Interventions: Other: Arterial Spin Labeling Magnetic Resonance Imaging

First Posted Date: 2008-09-09

Last Posted Date: 2020-02-26

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 32

Registration Number: NCT00749320

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Impaired Wound Healing in Diabetic Foot Ulceration

Completed

Conditions: Diabetes Mellitus
Healthy Volunteers

First Posted Date: 2008-08-21

Last Posted Date: 2017-03-01

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 137

Registration Number: NCT00739323

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Near-Infrared Fluorescent Sentinel Lymph Node Mapping for Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Device: NIR imaging system

First Posted Date: 2008-07-24

Last Posted Date: 2013-02-18

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 12

Registration Number: NCT00721370

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache

Phase 4

Completed

Conditions: Episodic Migraine

Interventions: Drug: placebo pills
Drug: Maxalt
Drug: placebo pill

First Posted Date: 2008-07-21

Last Posted Date: 2015-04-09

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 76

Registration Number: NCT00719134

Locations: 🇺🇸
Pain Clinic at Beth Israel Deaconess Medical Center, Brookline, Massachusetts, United States

Matrix Biology of Tracheobronchomalacia and Tracheal Stenosis

Completed

Conditions: Tracheobronchomalacia
Tracheal Stenosis

First Posted Date: 2008-06-26

Last Posted Date: 2017-03-21

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 16

Registration Number: NCT00705848

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant

Phase 1

Completed

Conditions: Acute Lymphocytic Leukemia
Relapsed/Refractory Chronic Lymphocytic Leukemia
Acute Myeloid Leukemia
Hodgkins Disease
Myelodysplastic Syndrome
Relapsed/Refractory Non Hodgkin's Lymphoma
Relapsed Refractory Multiple Myeloma

Interventions: Drug: Antithymocyte Globulin
Drug: Clofarabine

First Posted Date: 2008-06-16

Last Posted Date: 2023-11-28

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 29

Registration Number: NCT00697684

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Statin Therapy in the Treatment of Sepsis

Phase 2

Completed

Conditions: Septic Shock

Interventions: Drug: Simvastatin
Drug: Placebo

First Posted Date: 2008-05-13

Last Posted Date: 2017-06-14

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 18

Registration Number: NCT00676897

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy